Abstract
BackgroundElevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) of patients (pts) with rheumatoid arthritis (RA), resulting in the potential exclusion of pts with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
